Scientists at F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have divulged compounds acting as Toll-like receptor 7 (TLR7) and TLR8 agonists reported to be useful for the treatment of cancer.
At the recently concluded American Society of Hematology meeting, F Hoffmann-La Roche Ltd. presented promising results for their next-generation coagulation factor VIIIa (FVIIIa) mimetic bispecific antibody, NXT-007 (RO-7589655), supporting the ongoing phase I/II studies.
A patent from F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. describes bicyclic heterocycle 5'-nucleotidase (CD73) inhibitors reported to be useful for the treatment of cancer.
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have patented oxazolo[4,5-B]pyrazine and oxazolo[4,5-B]pyridine derivatives acting as NLRP3 inflammasome inhibitors and reported to be useful for the treatment of asthma, chronic obstructive pulmonary disease and cardiovascular disorders.
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have patented tricyclic compounds acting as UDP-2,3-diacylglucosamine hydrolase (LpxH) (bacterial) inhibitors and thus reported to be useful for the treatment of gram-negative bacterial infections.
Poseida Therapeutics Inc. has announced the nomination of a new development candidate under its collaboration with F. Hoffmann-La Roche Ltd., triggering a milestone payment from Roche to Poseida.
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have patented indazole compounds acting as membrane-associated tyrosine- and threonine-specific Cdc2-inhibitory kinase (PKMYT1) inhibitors reported to be useful for the treatment of cancer.
Researchers at F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have described C-C chemokine receptor type 6 (CCR6) antagonists reported to be useful for the treatment of asthma, psoriasis, Crohn’s disease, ulcerative colitis, multiple sclerosis, rheumatoid arthritis and systemic lupus erythematosus.
At the ongoing meeting of the American Chemical Society in Denver, F. Hoffmann-La Roche Ltd. has reported the discovery of an orally available and brain-penetrant irreversible asparagine-specific endopeptidase (AEP) inhibitor, RO-7542742, for the potential treatment of neurodegenerative diseases.
Researchers at F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have described GTPase KRAS mutant inhibitors, particularly KRAS G12C mutant, reported to be useful for the treatment of cancer.
